Helse Stavanger HF
- Address
- P. O. Box 8100, 4068 Stavanger, Norway
Helse Stavanger HF - Comprehensive Oncology and Specialized Disease Research Center
Helse Stavanger HF is a distinguished research institution conducting advanced clinical trials across multiple therapeutic areas, with particular strength in oncology and hematologic malignancies. The center demonstrates significant expertise in investigating novel targeted therapies and immunotherapies for complex cancer types, including studies on KRAS G12C-mutated non-small cell lung cancer, follicular lymphoma, and multiple myeloma.
- Hematologic malignancies including diffuse large B-cell lymphoma, follicular lymphoma, acute myeloid leukemia, and relapsed/refractory multiple myeloma
- Solid tumor oncology with focus on lung cancer, bladder cancer, colorectal cancer, and rare tumor types including neuroendocrine tumors and mesothelioma
- Neurological disorders and autoimmune conditions, particularly multiple sclerosis research
- Infectious diseases and specialized conditions including COVID-19, monkeypox, and chronic kidney disease with atrial fibrillation
The research center actively participates in international collaborative studies and platform trials, investigating cutting-edge treatments including immune checkpoint inhibitors, bispecific antibodies, and targeted molecular therapies. Their diverse portfolio extends to pediatric respiratory conditions and cardiovascular complications in complex patient populations, demonstrating a commitment to addressing unmet medical needs across the full spectrum of patient care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 31 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Helse Stavanger HF1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Helse Stavanger HF
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158) | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Feb 2016 | — |
IMP list
lock Showing 1 of 31 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 2 | Unknown | 2022-10-05 | 2023-01-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.